Ian Wilders, managing director of Labo’Life, a Spanish micro-immunotherapy specialist, discusses the company’s history and the importance of regulatory reform in giving them greater market access and shifting the mindset of doctors. Furthermore, he touches on the company’s international strategy and the importance of a personalized care approach.
Our challenge is defining the regulatory framework in which we are classed, so in the end, patients can receive our therapies
The executive president of Laboratorios Rubió, Carlos Rubió, analyses the fundamentals behind the Catalan company’s double-digit growth, its international expansion plan, which includes the United States, the doubling of capacity…
The Spanish Association of Orphan and Ultra Orphan Medicinal Products Laboratories (AELMHU) is a non-profit organisation working to improve awareness about rare diseases and access of Orphan Drugs. Maria Jose…
Maria Jose Sanchez Losada, general manager for CSL Behring Iberia, highlights the challenges that plasma-derived therapies faced during the COVID-19 pandemic, how the firm competes with well-established local players in…
Based on IQVIA’s pharma market rankings for 2020, we give a rundown of the global top 10, key companies, important trends, and where you can go to learn more. …
According to recent IQVIA and industry association reports, the Spanish pharma market, valued at EUR 21.6 billion per year, continues to grow at a relatively slow pace. Other key trends…
A rundown of five things to know about the healthcare and life sciences industry in Catalonia. Nestled in Northeastern Spain and bordering France, Catalonia’s capital and largest city is Barcelona.…
See our Cookie Privacy Policy Here